Eli Lilly and Company (NYSE: LLY) is a leading global pharmaceutical company with a strong track record of innovation and growth. As investors look to the future, many are wondering what the outlook is for Eli Lilly’s stock price in the coming years and decades. In this article, we provide a comprehensive analysis of Eli Lilly’s stock price forecasts from 2024 to 2050, based on the company’s fundamentals, market trends, and growth prospects.
Key Takeaways:
- Eli Lilly’s stock price is projected to experience strong growth from 2024-2050, driven by its robust drug pipeline, expanding markets, and solid financials
- We forecast Eli Lilly’s stock price could reach $6,500 by 2050, representing a compound annual growth rate (CAGR) of 8.4% from the current price of $803.17 as of May 21, 2024
- Eli Lilly is well-positioned to deliver above-market returns for long-term investors, but the stock may experience volatility along the way
Overview of Eli Lilly and Company
Eli Lilly and Company was founded in 1876 and has grown to become one of the largest pharmaceutical companies in the world. Throughout its history, Lilly has discovered and developed many breakthrough drugs across multiple therapeutic areas including diabetes, oncology, immunology, and neuroscience. Some of the company’s blockbuster products include Trulicity, Jardiance, Verzenio, Taltz, and Cyramza.
Eli Lilly Company Profile
| Country | United States |
| Ticker Symbol | LLY |
| Exchange | New York Stock Exchange (NYSE) |
| Founded | 1876 |
| IPO Date | 1978 |
| Industry | Drug Manufacturers – General |
| Sector | Healthcare |
| Employees | 43,000 |
| CEO | Mr. David A. Ricks |
| Market Cap (May 20, 2024) | $744.34 billion |
| Website | lilly |
Eli Lilly (LLY) Balance Sheet Analysis
Eli Lilly and Company (NYSE: LLY) reported a strong financial position in its 2023 balance sheet. Total assets reached $64.01 billion, driven by investments in research and development and an expanding product portfolio. Liabilities, net of minority interest, increased to $53.14 billion, reflecting the company’s efforts to fund growth initiatives.
Eli Lilly’s total equity, gross of minority interest, stood at $10.86 billion, with common stock equity at $10.77 billion. Total capitalization reached $29.09 billion, showcasing the company’s strong financial position and cash flow generation.
Net tangible assets were negative $1.07 billion due to investments in intangible assets. Working capital turned negative at $1.57 billion, possibly due to increased short-term liabilities or changes in cash management.
Total debt increased to $25.23 billion, with net debt reaching $22.41 billion, as the company financed growth initiatives. Despite increased liabilities and debt, Eli Lilly’s growing assets and equity demonstrate its continued success in the pharmaceutical industry.
Balance Sheet Data Source: finance.yahoo
Eli Lilly Stock Price History
Eli Lilly and Company (LLY) went public in the year 1978. Eli Lilly (LLY) has undergone four stock splits since 1986, with the most recent occurring on October 16, 1997. The company also split its stock in 1995, 1989, and 19861. The cumulative effect of these splits means that one LLY share purchased before January 30, 1986, would now equate to 16 shares, reflecting the company’s growth and increasing shareholder value.
As of May 21, 2024, the stock stands at $803.17.
Eli Lilly Stock Price Forecast 2024
We expect Eli Lilly will continue its momentum in 2024, driven by strong growth for key products like Trulicity, Verzenio, and Taltz, and potential new launches. The company’s fundamentals remain sound, with a robust late-stage pipeline, expanding margins, and strong cash flows. Risks include drug pricing reforms and increasing competition in certain categories.
For 2024, we forecast the following price ranges for Eli Lilly stock:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2024 | $775 | $850 | $925 |
Our 2024 base case price target of $850 represents 5.8% upside from the current price of $803.17 as of May 21, 2024.
Eli Lilly Stock Price Forecast 2025
Looking ahead to 2025, we anticipate Eli Lilly will continue to generate steady top and bottom-line growth, supported by its diverse product portfolio and pipeline advancements. Key growth drivers may include Trulicity, Verzenio, Taltz, lebrikizumab, Mounjaro, and donanemab. However, loss of exclusivity for some products could create headwinds.
For 2025, we model the following price ranges for Eli Lilly stock:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2025 | $825 | $925 | $1,025 |
Our 2025 base case estimate of $925 implies a 9.4% increase from our 2024 price target and a 15.2% rise from the May 21, 2024 price.
Eli Lilly Stock Price Forecast 2026
We expect 2026 to be another solid year for Eli Lilly, buoyed by continued growth from its core diabetes and immunology franchises, expansion into new indications, and progress in its Alzheimer’s pipeline. Operating leverage and financial discipline should support margin expansion and earnings growth.
We forecast the following price ranges for Eli Lilly stock in 2026:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2026 | $900 | $1,000 | $1,150 |
Our 2026 average price target of $1,000 represents an 8.1% increase from our 2025 forecast and a 24.5% gain from the current price.
Eli Lilly Stock Price Forecast 2027
For 2027, we model steady growth across Eli Lilly’s core business segments, augmented by new product launches, label expansions, and selective business development. The company’s late-stage pipeline remains robust, with several potential blockbuster drugs in obesity, pain, and immunology. Patent expirations and drug pricing pressure are risks to monitor.
Our projected price ranges for Eli Lilly stock in 2027 are as follows:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2027 | $1,000 | $1,125 | $1,250 |
The $1,125 average price target for 2027 is 12.5% above our 2026 estimate and 40.0% higher than the May 21, 2024 price.
Eli Lilly Stock Price Forecast 2028
We expect Eli Lilly will deliver another year of solid top and bottom-line growth in 2028, propelled by its market-leading diabetes portfolio, growing presence in immunology, and advancement of its innovative mid-to-late stage pipeline. Operating margin expansion and share buybacks could provide additional boosts to EPS. Increasing competition is a key risk.
For 2028, we forecast the following price ranges for Eli Lilly stock:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2028 | $1,150 | $1,275 | $1,400 |
Our base case 2028 price target of $1,275 represents a 13.3% rise from our 2027 forecast and a 58.7% increase from the current price.
Eli Lilly Stock Price Forecast 2029
Looking ahead to 2029, we see multiple potential catalysts that could drive outperformance for Eli Lilly stock, including market share gains for key products, approval of new blockbuster drugs, operating leverage, and financial discipline. Potential headwinds include drug pricing reforms, competition, and pipeline setbacks.
We project the following price ranges for Eli Lilly stock in 2029:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2029 | $1,325 | $1,450 | $1,600 |
The average price target of $1,450 for 2029 is 13.7% higher than our 2028 estimate and 80.5% above the May 21, 2024 price.
Eli Lilly Stock Price Forecast 2030
For 2030, we expect Eli Lilly’s strong growth trajectory to continue, led by its diverse product portfolio, solid pipeline, and ongoing margin expansion. The company is well-positioned to benefit from secular growth trends in areas like diabetes, obesity, immunology, and neuroscience. Pricing pressure and loss of exclusivity for certain drugs are potential risks.
Our forecasted price ranges for Eli Lilly stock in 2030 are as follows:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2030 | $1,500 | $1,650 | $1,800 |
We estimate Eli Lilly stock could reach an average price of $1,650 in 2030, representing a 13.8% increase from our 2029 target and a 105.4% gain from the current price.
Related: Mastercard (MA) Stock Forecast & Price Prediction
Eli Lilly Stock Price Forecast 2031
We anticipate 2031 will be another year of steady growth for Eli Lilly, supported by its market-leading positions in key therapeutic areas, advancement of its innovative pipeline, and disciplined expense management. Potential new product launches and label expansions could provide additional upside. Patent cliffs and drug pricing reforms remain risks.
For 2031, we model the following price ranges for Eli Lilly stock:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2031 | $1,700 | $1,875 | $2,075 |
Our base case 2031 price target of $1,875 is 13.6% higher than our 2030 forecast and represents a 133.4% increase from the May 21, 2024 price.
Eli Lilly Stock Price Forecast 2032
Looking ahead to 2032, we expect Eli Lilly’s positive momentum to persist, driven by continued strength in its core franchises, new product launches, operating leverage, and shareholder-friendly capital deployment. The company’s robust early-stage pipeline provides additional long-term upside potential. Competition and payer pressure are key risks.
We forecast the following price ranges for Eli Lilly stock in 2032:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2032 | $1,900 | $2,100 | $2,300 |
The average price target of $2,100 for 2032 represents a 12.0% rise from our 2031 estimate and a 161.5% increase from the current price.
Eli Lilly Stock Price Forecast 2033
For 2033, we model another solid year of growth for Eli Lilly, supported by its diversified business model, strong pipeline, and commitment to innovation. Margin expansion and financial discipline should provide a tailwind to earnings growth. Loss of exclusivity for certain drugs and increasing competition are potential headwinds.
Our projected price ranges for Eli Lilly stock in 2033 are as follows:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2033 | $2,150 | $2,350 | $2,600 |
We estimate Eli Lilly stock could reach an average price of $2,350 in 2033, representing an 11.9% increase from our 2032 target and a 192.5% gain from the May 21, 2024 price.
Eli Lilly Stock Price Forecast 2034
We expect Eli Lilly will continue to deliver solid growth in 2034, propelled by its robust product portfolio, pipeline advancements, and strong commercial execution. The company is well-positioned to benefit from positive demographic trends and increasing demand for innovative medicines. Pricing pressure and regulatory changes are risks to monitor.
For 2034, we forecast the following price ranges for Eli Lilly stock:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2034 | $2,400 | $2,600 | $2,900 |
Our 2034 base case price target of $2,600 implies a 10.6% increase from our 2033 forecast and a 223.6% rise from the current price.
Eli Lilly Stock Price Forecast 2035
Looking ahead to 2035, we anticipate Eli Lilly’s growth to remain strong, supported by its diverse revenue streams, innovative pipeline, and operating efficiency. The company is well-equipped to navigate evolving industry dynamics and capitalize on new growth opportunities. Drug pricing reforms and increasing competition are potential risks.
We model the following price ranges for Eli Lilly stock in 2035:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2035 | $2,700 | $2,900 | $3,200 |
The average price target of $2,900 for 2035 represents an 11.5% rise from our 2034 estimate and a 261.1% increase from the May 21, 2024 price.
Eli Lilly Stock Price Forecast 2036
For 2036, we expect Eli Lilly to deliver another year of solid growth, driven by its market-leading franchises, pipeline successes, and financial discipline. The company’s early-stage pipeline provides additional long-term optionality. Loss of exclusivity for certain products and payer pressure are potential headwinds.
Our forecasted price ranges for Eli Lilly stock in 2036 are as follows:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2036 | $3,000 | $3,250 | $3,500 |
We estimate Eli Lilly stock could reach an average price of $3,250 in 2036, representing a 12.1% increase from our 2035 target and a 304.6% gain from the current price.
Eli Lilly Stock Price Forecast 2037
We anticipate Eli Lilly’s positive momentum will persist in 2037, supported by its diversified business model, strong commercial capabilities, and R&D productivity. Margin expansion and capital deployment should provide additional upside. Increasing competition and drug pricing pressure are risks to monitor.
For 2037, we model the following price ranges for Eli Lilly stock:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2037 | $3,400 | $3,650 | $4,000 |
Our base case 2037 price target of $3,650 is 12.3% higher than our 2036 forecast and represents a 354.4% increase from the May 21, 2024 price.
Eli Lilly Stock Price Forecast 2038
Looking ahead to 2038, we expect Eli Lilly to deliver solid growth, propelled by its robust product portfolio, pipeline advancements, and operating efficiency. The company is well-positioned to benefit from positive secular trends and increasing global demand for healthcare. Patent expirations and regulatory changes are potential risks.
We forecast the following price ranges for Eli Lilly stock in 2038:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2038 | $3,800 | $4,100 | $4,500 |
The average price target of $4,100 for 2038 represents a 12.3% rise from our 2037 estimate and a 410.4% increase from the current price.
Eli Lilly Stock Price Forecast 2039
For 2039, we model another year of steady growth for Eli Lilly, supported by its diverse revenue streams, innovative pipeline, and strong commercial execution. The company’s early-stage pipeline provides additional long-term growth potential. Pricing pressure and increasing competition are risks to watch.
Our projected price ranges for Eli Lilly stock in 2039 are as follows:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2039 | $4,300 | $4,600 | $5,000 |
We estimate Eli Lilly stock could reach an average price of $4,600 in 2039, representing a 12.2% increase from our 2038 target and a 472.7% gain from the May 21, 2024 price.
Eli Lilly Stock Price Forecast 2040
We expect Eli Lilly’s strong growth trajectory to continue in 2040, driven by its market-leading positions, pipeline successes, and financial discipline. The company is well-equipped to navigate evolving industry dynamics and capitalize on new growth opportunities. Loss of exclusivity for certain drugs and regulatory changes are potential headwinds.
For 2040, we forecast the following price ranges for Eli Lilly stock:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2040 | $4,800 | $5,200 | $5,600 |
Our 2040 base case price target of $5,200 implies a 13.0% increase from our 2039 forecast and a 547.4% rise from the current price.
Eli Lilly Stock Price Forecast 2050
Looking further out to 2050, we anticipate Eli Lilly will continue to generate solid growth and create shareholder value, supported by its strong fundamentals, innovation capabilities, and global scale. The company is well-positioned to benefit from positive long-term demographic and socioeconomic trends, while adapting to evolving healthcare needs and technologies. Risks include increasing competition, drug pricing reforms, and patent expirations.
We model the following price ranges for Eli Lilly stock in 2050:
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2050 | $6,000 | $6,500 | $7,000 |
Our base case estimate of $6,500 for 2050 represents a 709.3% increase from the May 21, 2024 price, implying a compound annual growth rate (CAGR) of 8.4% over the 26-year period.
Conclusion
Eli Lilly and Company is a global pharmaceutical leader with a strong track record of innovation, growth, and shareholder value creation. Our analysis suggests Eli Lilly’s stock price could appreciate significantly in the coming years and decades, driven by its diversified product portfolio, robust pipeline, expanding markets, and operational excellence.
We forecast Eli Lilly’s stock price could reach $6,500 by 2050, representing a CAGR of 8.4% from the current price of $803.17 as of May 21, 2024. While the journey may not be linear, we believe Eli Lilly is well-positioned to outperform the broader market over the long run, making it an attractive holding for growth-oriented investors.
FAQs
1. What will Eli Lilly stock be worth in 5 years?
Based on our analysis, we forecast Eli Lilly’s stock price could reach an average of $1,450 by 2029, which is roughly 5 years from now. This represents an 80.5% increase from the current price of $803.17 as of May 21, 2024. However, these projections are based on current assumptions and are subject to change based on various factors.
2. Is Eli Lilly a good long-term stock?
Yes, we believe Eli Lilly is a good long-term stock for growth-oriented investors. The company has a strong track record of innovation, a diversified product portfolio, a robust pipeline, and solid financials. We expect Eli Lilly to outperform the broader market over the long run, driven by its leadership in key therapeutic areas and expanding global presence.
3. What is the future of Eli Lilly stock?
We anticipate Eli Lilly’s stock will appreciate significantly in the coming years and decades, supported by its strong fundamentals, operational excellence, and growth prospects. Our base case forecast suggests Eli Lilly’s stock price could reach $6,500 by 2050, implying a compound annual growth rate (CAGR) of 8.4% from the current price. However, the stock may experience volatility along the way due to various risks and uncertainties.
4. Who owns the most Eli Lilly stock?
As of recent filings, the largest institutional holders of Eli Lilly stock include The Lilly Endowment, The Vanguard Group, BlackRock Fund Advisors, and Fidelity Management & Research Co., among others. Eli Lilly also has a large base of individual shareholders, including company executives, employees, and retail investors.
5. Is Eli Lilly a Fortune 500 company?
Yes, Eli Lilly and Company is a Fortune 500 company, ranking among the 50 largest corporations in the United States by total revenue. In the 2023 Fortune 500 list, Eli Lilly ranked #87, reflecting its significant scale and impact on the global pharmaceutical industry.
Disclaimer:
The stock price predictions provided herein are based on historical data, current market trends, and analysis. However, past performance does not guarantee future results. Stock markets are inherently volatile and subject to numerous economic, political, and market factors that can cause rapid and unpredictable fluctuations in stock prices. The information provided is for educational and informational purposes only and should not be construed as financial advice. It is strongly recommended that you consult with a qualified financial advisor before making any investment decisions. Invest responsibly and consider your individual financial situation, risk tolerance, and investment objectives before acting on any information provided.
Source:
